Clinical summary
Summary
Eligible participants will be randomly allocated to either the Standard Arm or the Experimental Arm. In the Standard Arm, participants will receive large en-bloc curative-intent surgery within 4 weeks following randomisation. In the Experimental Arm, participants will receive 3 cycles of neoadjuvant chemotherapy starting within 2 weeks following randomisation. People with liposarcoma will receive ADM (doxorubicin) 75mg/m2 (or the equivalent EpiADM 120mg/m2) + ifosfamide 9g/m3 every 3 weeks. People with leiomyosarcoma will receive ADM 75mg/m2 + DTIC (dacarbazine) 1g/m2 every 3 weeks. Following this, participants in the experimental arm will be re-assessed to determine whether surgery can proceed. If yes, curative-intent surgery will be performed within 3-6 weeks of last cycle of chemotherapy.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
European Organisation for Research and Trearment of Cancer (EORTC)
Scientific Title
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)